Replies to post #24 on Tibet Pharmaceuticals, Inc. (TBET)

[Bull Trader]

NASDAQ: TBET (.72) Why this is MAJORLY undervalued:
Tibet Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Tibetan medicines.

http://www.tibetpharmaceuticals.com/

$26 Million CASH ON HAND
($1.75 per share)
Book Value per share: $3.18

$34 Million in Revenues
31% profit margin

Market Cap: $11 Million
http://finance.yahoo.com/q/ks?s=TBET+Key+Statistics

The stock IPO'd around 4.50 in April 2011 and since then has declined on very little volume. The overall lack of interest in Chinese companies for the past year has contributed greatly to the decline as investors have been weary of the accounting issues by several other Chinese companies.

TBET, however, has a strong balance sheet and based on this past Friday Feb. 24th's volume - an all time high for volume - may have just finally peaked the interest of investors.
http://finance.yahoo.com/news/Nasdaq-stocks-posting-largest-apf-121919750.html?x=0

Take a look at the chart here: http://stockcharts.com/c-sc/sc?s=TBET&p=D&yr=1&mn=0&dy=0&i=t83597123101&r=3473

The company has several drugs in development including a diabetes drug in Phase III as well as an impotence drug:
Shengke I that is in Phase III clinical testing for treating type II diabetes; Shengke II, which is in Phase II clinical testing for treating impotence and premature ejaculation, prostrate disease, and memory loss; Jiuzan pill that is in Phase II clinical testing for the treatment of chronic gastroenteritis and peptic ulcers; and Antai pill, a pre-clinical stage product for treating hepatitis B.
http://finance.yahoo.com/q/pr?s=TBET+Profile

Based on the strong financial position of the company, its strong drug pipeline, and the very low price per share, TBET could present investors with an excellent opportunity to see some major gains.